MU Health - University Hospital/Ellis Fischel Cancer Center Trials

MU Health - University Hospital/Ellis Fischel Cancer Center	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Contact, Site Public

iinnovate-1, NCT03215030: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Active, not recruiting

1/2

336

Europe, Canada, Japan, US, RoW

Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone

Takeda

Multiple Myeloma

02/24

09/24

NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Active, not recruiting

1/2

Europe, US, RoW

Ponatinib, Ponatinib AAF, Chemotherapy Agents

Takeda, Takeda Development Center Americas, Inc.

Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)

12/24

01/27

COBRA, NCT05220098: First-in-Human Study of TAK-280 in Participants With Solid Tumors

Recruiting

1/2

182

Europe, Canada, US, RoW

TAK-280

Takeda, Takeda Development Center Americas, Inc.

Unresectable Locally Advanced or Metastatic Cancer

02/25

07/26

iinnovate-3, NCT05590377 / 2022-002169-14: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma

Active, not recruiting

1/2

Europe, Canada, US, RoW

Modakafusp Alfa, TAK-573, Daratumumab

Takeda, Takeda Development Center Americas, Inc.

Multiple Myeloma

03/25

NCT05070247: A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Recruiting

1/2

313

TAK-500, Pembrolizumab

Takeda

Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous

08/26

EXCLAIM, NCT02716116 / 2016-001271-68: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

	Presentation of data for EGFR Exon20 insertion+ metastatic 2L NSCLC at ASCO 2021
	May 2021 - May 2021: Presentation of data for EGFR Exon20 insertion+ metastatic 2L NSCLC at ASCO 2021
	For EGFR Exon20 insertion+ metastatic 2L NSCLC
	Jan 2021 - Jan 2021: For EGFR Exon20 insertion+ metastatic 2L NSCLC

Active, not recruiting

1/2

334

Europe, Japan, US, RoW

TAK-788, AP32788

Takeda

Carcinoma, Non-Small-Cell Lung

03/25

NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Recruiting

1/2

258

US, RoW

TAK-186, MVC-101

Takeda

Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer

09/25

11/26

Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting

1/2

368

Europe, Canada, Japan, US, RoW

Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil

Takeda, Takeda Development Center Americas, Inc. (TDC Americas)

Solid Neoplasms

01/26

NCT04381650 / 2020-004325-23: A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

Europe, Japan, US, RoW

TAK-981, Pembrolizumab

Takeda, Takeda Development Center Americas, Inc.

Advanced or Metastatic Solid Tumors

11/25

NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting

1/2

GDX012, Chemotherapy Agents

Takeda

Leukemia

04/26

06/27

NCT04964258: A Study of TAK-105 in Healthy Adults

Completed

TAK-105-a, TAK-105-a Placebo, TAK-105-b, TAK-105-b Placebo

Takeda

Healthy Volunteers

06/23

NCT05818956: A Study of TAK-227 in Healthy Adults

Completed

TAK-227

Takeda

Healthy Volunteers

06/23

NCT05602818: A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

Completed

Soticlestat 300 mg, Soticlestat 600 mg, Soticlestat 900 mg, Alprazolam, Placebo

Takeda

Healthy Volunteers

06/23

07/23

NCT05995249: A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Completed

172

TAK-279, Erythromycin, Phenytoin, Efavirenz

Takeda

Healthy Volunteers

12/23

NCT06132867: A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

Completed

Brigatinib, ALUNBRIG®

Takeda

Healthy Volunteers

02/24

NCT04879849: A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Completed

Pembrolizumab, TAK-676, Image-guided radiation therapy

Takeda

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck

04/24

NCT06258265: A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Recruiting

120

TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo

Takeda

Healthy Volunteers

06/24

07/24

NCT05976321: A Study of TAK-279 in Adults With or Without Liver Damage

Recruiting

TAK-279

Takeda

Hepatic Impairment, Healthy Volunteers

08/24

MT-0169-001, NCT04017130: A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

Terminated

MT-0169

Molecular Templates, Inc.

Relapsed and/or Refractory Multiple Myeloma

12/23

NCT05976334: An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors

Recruiting

Europe

[14C] Subasumstat, TAK-981, Subasumstat

Takeda

Solid Tumors

08/24

04/25

NCT06377228: A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)

Not yet recruiting

TAK-007, Chemotherapy Agents

Takeda

Refractory Lupus Nephritis

04/29

NCT06111547: A Study of TAK-279 in Healthy Chinese Adults

Recruiting

RoW

TAK-279, Placebo

Takeda

Healthy Volunteers

12/24

NCT05992155: A Study of TAK-279 in Adults With or Without Kidney Problems

Completed

TAK-279

Takeda

Renal Impairment, Healthy Volunteers

05/24

NCT05891158: A Study About Fazirsiran in People With and Without Liver Problems

Recruiting

Europe

Fazirsiran, TAK-999

Takeda

Hepatic Impairment

04/25

iinnovate-2, NCT05556616: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Active, not recruiting

120

Europe, US, RoW

Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide

Takeda

Multiple Myeloma

01/24

06/24

NCT05702424: Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

Active, not recruiting

IGM-7354

IGM Biosciences, Inc.

Solid Tumor

02/26

03/26

NCT05174221: A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Active, not recruiting

Europe, Japan, US, RoW

Mezagitamab, TAK-079

Takeda

Kidney Disease, Glomerulonephritis

03/26

NCT04506619 / 2020-002726-84: Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

Terminated

N/A

Europe, US

No Intervention

Oak Hill Bio Ltd

Retinopathy of Prematurity (ROP), Intraventricular Hemorrhage, Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity

08/22

EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed

N/A

179

Europe, Canada, RoW

Takeda

Non-small Cell Lung Cancer (NSCLC)

02/23

INTUITION-CPF, NCT04844593: A Study Using Artificial Intelligence to Identify Adults With Complex Perianal Fistulas Associated With Crohn's Disease

Completed

N/A

Europe

Takeda

Crohn Disease, Rectal Fistula

02/23

04/24

NCT05795361: Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Available

N/A

Europe, US, RoW

Idursulfase-IT, HGT-2310, TAK-609

Takeda

Hunter Syndrome

NCT05265078: A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi

Completed

N/A

102

Europe

Takeda

Von Willebrand Disease (VWD)

04/23

DOrianT, NCT04659798: A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice

Completed

N/A

240

Europe

Takeda

Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis

04/23

08/23

NCT04877431: A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease

Completed

N/A

RoW

Takeda

Short Bowel Syndrome

06/23

NCT04583007: Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

No Longer Available

N/A

Europe, Canada, US

Lanadelumab 150 mg, TAK-743, SHP643, DX-2930, Lanadelumab 300 mg

Shire, Takeda Development Center Americas, Inc.

Hereditary Angioedema (HAE), Angioedema

TAK-743-4008, NCT04955964: A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina

Completed

N/A

RoW

Takeda

Angioedemas, Hereditary

08/23

ermEX-20, NCT05419700: A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion

Completed

N/A

Europe

Takeda

Non-small Cell Lung Cancer (NSCLC)

09/23

NCT05695560: A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers

Completed

N/A

Canada

No Intervention

Takeda

Von Willebrand Disease (VWD)

11/23

REALM, NCT05506774: A Study of People With CD30 Positive Lymphoma in China

Active, not recruiting

N/A

2800

RoW

Takeda

Lymphoma

12/24

NCT05489640: A Study in Adults With Hereditary Angioedema (HAE) Who Currently Receive Icatibant at Home

Recruiting

N/A

100

Europe

No Intervention

Takeda

Hereditary Angioedema (HAE)

06/24

PROSPECT, NCT05578417: A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada

Recruiting

N/A

150

Canada

No Intervention

Takeda

Hereditary Angioedema (HAE), Angioedema

03/24

06/24

NCT03824522: Post Marketing Surveillance Study for ADYNOVATE in South Korea

Completed

N/A

341

RoW

ADYNOVATE, PEGylated rFVIII

Takeda, Takeda Pharma Korea Co. Ltd.

Hemophilia A

01/24

NCT04885920: A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)

Completed

N/A

120

Europe, RoW

Takeda

Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative

03/24

CREDIT, NCT05288491: A Study of Chinese Adults With Lymphoma

Recruiting

N/A

1000

RoW

Takeda

Lymphoma

06/24

NCT05371028: A Study of Teduglutide (Revestive®) in Participants With Short Bowel Syndrome (SBS) in Canada

Recruiting

N/A

100

Canada

Non-interventional Study

Takeda

Short Bowel Syndrome (SBS)

07/24

NCT05106764: Early Detection of Fabry Disease

Active, not recruiting

N/A

Europe

No intervention

Takeda

Fabry Disease

04/24

NCT04861233: A Study of Lubiprostone to Treat Constipation

Recruiting

N/A

3000

RoW

No Intervention

Jeil Pharmaceutical Co., Ltd.

Constipation

05/24

11/24

NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice

Active, not recruiting

N/A

500

RoW

Takeda

Colitis, Ulcerative, Crohn Disease

07/24

DRALEGA, NCT05982717: A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain

Recruiting

N/A

250

Europe

No intervention

Takeda

Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)

05/24

NCT04840680: A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)

Recruiting

N/A

165

RoW

No Intervention

Takeda

Multiple Myeloma

06/24

NCT05886478: A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin

Recruiting

N/A

Europe

No intervention

Takeda

T-Cell Lymphoma

06/24

mECHromatic, NCT05755568: A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain

Withdrawn

N/A

Europe

No Intervention

Takeda

Metachromatic Leukodystrophy (MLD)

07/24

NCT06346899: A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Not yet recruiting

N/A

130

RoW

No intervention

Takeda

Hereditary Angioedema (HAE)

08/25

ENABLE, NCT04130191: A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

Active, not recruiting

N/A

140

Europe, RoW

Shire, Takeda Development Center Americas, Inc.

Hereditary Angioedema (HAE)

09/24

LANDSCAPE, NCT04943796: A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life

Recruiting

N/A

576

Europe, Canada

Takeda

Attention Deficit Hyperactivity Disorder (ADHD)

09/24

INFINITE, NCT04328662: A Study of Ninlaro in Real World Clinical Practice in China

Active, not recruiting

N/A

482

RoW

Takeda

Multiple Myeloma, Neoplasms, Plasma Cell

09/25

NCT06104878: A Study in Adults With Advanced Classical Hodgkin's Lymphoma (cHL) in Brazil Treated With Brentuximab Vedotin Together With Chemotherapy Compared to Chemotherapy Alone

Withdrawn

N/A

200

RoW

No Intervention

Takeda

Hodgkin Lymphoma

10/24

ELEGANT, NCT05737849: A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China

Withdrawn

N/A

10800

RoW

No Intervention

Takeda

Non-small Cell Lung Cancer (NSCLC)

12/24

NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Recruiting

N/A

1000

RoW

No Intervention

Takeda

Lymphoma

01/25

SUNRISE, NCT05192863: A Study of Vedolizumab in Adults With Crohn's Disease (CD)

Active, not recruiting

N/A

Europe, Canada, RoW

No Intervention

Takeda

Crohn's Disease

01/25

PEDS, NCT04721366: A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

Completed

N/A

Standard of Care, SOC

Takeda

Gaucher Disease

04/23

NCT05626088: A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

Recruiting

N/A

2160

RoW

No Intervention

Takeda

Ulcerative Colitis, Crohn's Disease

01/25

HyMMy, NCT05879757: Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

Recruiting

N/A

100

Europe, RoW

No Intervention

Takeda

Multiple Myeloma, Secondary Immunodeficiency (SID)

07/25

03/26

LEADER, NCT04985643: A Study of Real Life Treatment for Multiple Myeloma (MM)

Recruiting

N/A

111

RoW

Takeda

Multiple Myeloma

08/25

VARIETY, NCT05384080: A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Active, not recruiting

N/A

165

Europe

Takeda

Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis

08/25

NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Recruiting

N/A

320

RoW

No intervention

Takeda

Multiple Myeloma

10/25

NCT04961840: A Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy

Active, not recruiting

N/A

100

No Intervention

Takeda

Constipation, Pregnancy

12/25

NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

Recruiting

N/A

600

RoW

Takeda

Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease

01/26

CHOPIN, NCT05147181: A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

Recruiting

N/A

Europe

Takeda

Hereditary Angioedema (HAE)

03/26

NCT04869280: Post-Marketing Study of Prucalopride Safety In Pregnancy

Recruiting

N/A

616

No Intervention

Takeda, The Organization of Teratology Information Specialists

Chronic Idiopathic Constipation (CIC)

05/26

BV-MAZOVIA, NCT05100056: A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

Recruiting

N/A

Europe

No Intervention

Takeda

Hodgkin Lymphoma

06/26

NCT04838522: A Study of Prucalopride in Breastfeeding Women With Constipation

Recruiting

N/A

No Intervention

Takeda, UC San Diego Human Milk Research Biorepository

Chronic Idiopathic Constipation (CIC)

12/26

NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Recruiting

N/A

3000

Europe, RoW

Shire, Takeda Development Center Americas, Inc.

Hereditary Angioedema (HAE)

01/27

ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC)

Recruiting

N/A

Europe

No intervention

Takeda

Non-small Cell Lung Cancer (NSCLC)

06/27

NCT05428345: A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Recruiting

N/A

600

RoW

Takeda

Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease (IBD)

11/27

NCT04158934: A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

Active, not recruiting

N/A

207

Europe, US, RoW

ADYNOVI/ADYNOVATE, Antihaemophilic Factor [Recombinant] PEGylated rurioctocog alfa pegol, TAK-660, BAX 855

Baxalta now part of Shire

Hemophilia A

02/30

PARADIGHM, NCT01922440: A Registry for Participants With Chronic Hypoparathyroidism

Active, not recruiting

N/A

1340

Europe, Canada, US

No intervention

Takeda, Takeda Development Center Americas, Inc.

Hypoparathyroidism

11/34

Delacroix, Scott E

STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting

188

Canada, US

Radiation Therapy, RT, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoldaex®, Trelstar®

RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc

Prostate Cancer

04/23

09/29

Qadir, Misbah U

NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting

450

DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine

Delta-Fly Pharma, Inc.

Leukemia, Myeloid, Acute

12/22

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma

01/28

05/35

DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI

Recruiting

1100

Canada, US

Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20

SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP

Multiple Myeloma

07/29

07/40

NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting

186

Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited

CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation

10/24

06/25

Vogel, Mary T Jenkins

NCT05921149: Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer

Not yet recruiting

N/A

170

Fasting Mimicking Diet (Xentigen by L'Nutra), Carboplatin, Paclitaxel, Standard diet

NorthShore University HealthSystem, L-Nutra Inc

Ovarian Cancer, Chemotherapeutic Toxicity

06/28

06/31

Chalasani, Pratima

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

NCT04647916: Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting

Sacituzumab Govitecan, hRS7-SN38 Antibody Drug Conjugate, IMMU-132, RS7-SN38, Sacituzumab Govitecan-hziy, Trodelvy

SWOG Cancer Research Network, National Cancer Institute (NCI), Gilead Sciences

Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8

02/25

12/26

NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting

1/2

390

ACR-368, prexasertib, Gemcitabine, OncoSignature

Acrivon Therapeutics, GOG Foundation

Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma

07/26

12/27

Johnson, Scott

LEGEND study, NCT04752722: LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Recruiting

1/2

222

EG-70 (phase 1), Phase 1, EG-70 (phase 2), Phase 2

enGene, Inc.

Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

06/25

05/27

Siddique, Shahzad

A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI

Recruiting

1100

Canada, US

Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20

SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP

Multiple Myeloma

07/29

07/40

CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

2/3

1912

Canada, US

Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month

NRG Oncology, Natera, Inc., National Cancer Institute (NCI)

Stage III Colon Cancer

03/29

03/30

A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Recruiting

124

Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation

Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation

10/24

NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting

186

Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited

CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation

10/24

06/25

Forman, Adam M

ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting

200

Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)

Shanghai Henlius Biotech

Extensive Stage Small Cell Lung Cancer

10/24

12/25

NCT03994796: Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Recruiting

186

Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib, MRTX849

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Mirati Therapeutics Inc., Genentech, Inc., Eli Lilly and Company, Kazia Therapeutics Limited

CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation

10/24

06/25

NCT05633615: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting

396

Axicabtagene Ciloleucel, KTE C19, KTE-C19, KTE-C19 CAR, Yescarta, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Lisocabtagene Maraleucel, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017, Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017, Breyanzi, JCAR 017, JCAR017, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tisagenlecleucel, CART-19, CART19, CTL019, CTL019 T-cells, Kymriah, Tisagenlecleucel-T

SWOG Cancer Research Network, National Cancer Institute (NCI), Genentech, Inc.

Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Follic Lymph to Diff Large B-Cell Lymphoma, Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma

12/25

12/29

Isaak, Robert J

VOICE, NCT04648020: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

Terminated

190

Europe, US

Clonidine HCl Mucoadhesive Buccal Tablet, Validive®, Placebo Mucoadhesive Buccal Tablet

Monopar Therapeutics

Chemoradiotherapy-Induced Severe Oral Mucositis

05/23

Hallak, Mohammed Naieb Al

GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting

2/3

700

GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin

Gritstone bio, Inc.

Colorectal Neoplasms

03/27

NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Recruiting

250

Europe, Canada, Japan, US, RoW

zenocutuzumab (MCLA-128), bispecific, MCLA-128

Merus N.V.

Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion

12/26

STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting

AlloStim, StimVax

Immunovative Therapies, Ltd., Mirror Biologics, Inc.

Metastatic Colorectal Cancer

11/24

04/25

ELIMYN18.2, NCT04404595: Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Active, not recruiting

1/2

110

Canada, US

CT041

CARsgen Therapeutics Co., Ltd.

Gastric Cancer, Pancreatic Cancer

06/25

09/35



	Diseases Companies Products Productz Mechanisms of Action Sites